C.A.R.E Login
User ID 
Forgot your Password?   Reset
New User?   Register
  Novartis Pharma US

About The CNR
The Clozaril National Registry (CNR) is the benchmark for safety of patients being treated with Clozaril® (clozapine).
Tell Me More...
CARE System Features
CARE is a web based system for reporting required WBC/ANC values for patients taking brand Clozaril®. The features include WBC/ANC reporting from any P.C. with internet access, ability to view WBC/ANC history of registered patients, on-line patient registration requests, pharmacy search capability (to locate CNR pharmacy participants), and specialized patient grouping capabilities.
Learn More...
Sign up for CARE Today
Click here to register your access to CARE. Once you have logged in, take the interactive learning tour of our multi-functionalized site to better serve your patient safety needs.
Register Now...
Clozaril (clozapine) use is associated with a substantial risk of seizure, affected 1% to 2% of patients at low doses (below 300 mg/day), 3% to 4% at moderate doses (300 mg/day to 600 mg/day), and 5% at high doses (600 mg/day to 900 mg/day). Clozaril is contraindicated in patients with paralytic ileus. In clinical trials, Clozaril was associated with a 1% to 2% incidence of agranulocytosis, a potentially fatal blood disorder, which, if caught early, can be reversed. Mandatory monitoring of WBC counts and ANC's and drug dispensing as per the requirements specified in the package insert, provide an efficient means of determining developing agranulocytosis. Analysis of post-marketing safety databases suggests that Clozaril is associated with an increased risk of fatal myocarditis, especially during, but not limited to, the first month of therapy. Orthostatic hypotension may occur in some patients, especially during the initial phases of treatment, and can, in rare cases (approximate incidence of 1/3000), be accompanied by collapse and/or cardiac arrest. Analysis of clinical studies reveal that elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Patients with an established diagnosis of diabetes mellitus who are started on CLOZARIL should be monitored regularly for worsening glucose control (e.g., polydipsia, polyuria, polyphagia, and weakness).

Clozaril logo
Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2003
Novartis Pharmaceuticals Corporation. All rights reserved.